Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ERIS.NSthis companyEris Lifesciences Limited	₹1,255.50	28.62×	4.54×	5.67×	18.04×	108.8%	47.9%	26.9%	19.8%	15.9%	12.6%	0.3%	0.6×	2.07×	4.36×	0.74×	0.0%	5	3.5	3	B+
APLLTD.NSAlembic Pharmaceuticals Limited	₹1,017.30	19.32×	2.3×	1.77×	12.9×	3.1%	45.1%	10.9%	9.2%	11.9%	10.4%	2.0%	0.25×	1.11×	8.54×	1.76×	1.7%	4	—	2	B-
ASTRAZEN.NSAstraZeneca Pharma India Limited	₹6,529.00	103.53×	22.24×	8.53×	66.87×	74.4%	26.5%	10.3%	8.2%	21.5%	17.0%	0.0%	0.13×	-1.18×	51.99×	1.77×	0.4%	3	—	2	C+
BLISSGVS.NSBliss GVS Pharma Limited	₹654.75	18.76×	2.03×	2.61×	10.25×	-99.6%	54.2%	14.1%	13.9%	10.8%	7.3%	3.4%	0.02×	-0.06×	10.87×	4.02×	0.4%	6	17.76	3	B
GUFICBIO.NSGufic Biosciences Limited	₹474.35	42.78×	4.13×	2.91×	19.97×	-117.2%	36.0%	12.8%	6.8%	9.7%	8.1%	-0.7%	0.61×	2.13×	3.29×	1.55×	0.0%	6	—	1	C-
IPCALAB.NSIpca Laboratories Limited	₹1,959.70	35.6×	5.04×	4.21×	20.83×	-60.6%	64.1%	24.2%	11.8%	14.2%	16.5%	1.2%	0.1×	0.12×	30.7×	2.76×	0.1%	6	12.14	2	C
Peer median	—	35.6×	4.13×	2.91×	19.97×	-60.6%	45.1%	12.8%	9.2%	11.9%	10.4%	1.2%	0.13×	0.12×	10.87×	1.77×	0.4%	6	14.95	2	—